Market Research Logo

Hemarina SA - Product Pipeline Analysis, 2018 Update

Summary

Hemarina SA (Hemarina) is a biotechnology company that research and develop marine oxygen carriers for therapeutic and industrial uses. The company develops hemoglobin-based oxygen carriers (HBOCs) for organ preservation. It provides an additive for organ preservation solution, oxygenating dressing for hypoxic and chronic wounds, oxygen carriers, and a cell growth activator for cell culture and recombinant protein production for research and development laboratories. The company offers lead product, Hemarina M-101, which is under development that uses molecular-weight extracellular hemoglobin. The company has operational presence in the US and Noirmoutier Island. Hemarina is headquartered in Saint-Malo, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Hemarina SA
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Hemarina SA Company Overview
Hemarina SA Company Snapshot
Hemarina SA Pipeline Products and Ongoing Clinical Trials Overview
Hemarina SA – Pipeline Analysis Overview
Hemarina SA - Key Facts
Hemarina SA - Major Products and Services
Hemarina SA Pipeline Products by Development Stage
Hemarina SA Pipeline Products Overview
HEMHealing
HEMHealing Product Overview
HEMO2life
HEMO2life Product Overview
HEMOXYCarrier
HEMOXYCarrier Product Overview
Hemarina SA - Key Competitors
Hemarina SA - Key Employees
Hemarina SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Hemarina SA, Recent Developments
Nov 14, 2017: Brest University Hospital and HEMARINA announce positive Top-line results from first clinical trial of HEMO2life in kidney preservation before human transplantation.
Jul 26, 2016: Kidney transplant: OxyOp multicenter clinical trial evaluating the use of the oxygen carrier HEMO2life will continue in accordance with the protocol established
Feb 09, 2016: Business France Announces Creative Next U.S. Contest Winner
Feb 11, 2014: HEMARINA, ORPHY, the UBO laboratory, and the University Hospital of Brest launch HEMOXYCHOC, the preclinic project designed to assess the efficacy & safety of HEMOXYCarrier in the management of uncontrolled hemorrhagic shock
Sep 26, 2013: HEMARINA & LFB Biomanufacturing announced the signature of an agreement for the manufacturing of HEMO2life
Apr 30, 2013: HEMARINA expands its operations to Boston U.S.A. Hemarina will be the company affiliate for the America
Nov 07, 2011: ANR selects Hemarina’s HEMO2Perf project
Aug 31, 2011: Hemarina Announces Publication of HEMO2Life in American Journal of Transplantation
Feb 28, 2011: HEMARINA Signs Research Agreement to Study
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Hemarina SA Pipeline Products and Ongoing Clinical Trials Overview
Hemarina SA Pipeline Products by Equipment Type
Hemarina SA Pipeline Products by Indication
Hemarina SA, Key Facts
Hemarina SA, Major Products and Services
Hemarina SA Number of Pipeline Products by Development Stage
Hemarina SA Pipeline Products Summary by Development Stage
HEMHealing - Product Status
HEMHealing - Product Description
HEMO2life - Product Status
HEMO2life - Product Description
HEMOXYCarrier - Product Status
HEMOXYCarrier - Product Description
Hemarina SA, Key Employees
Hemarina SA, Subsidiaries
Glossary
List of Figures
Hemarina SA Pipeline Products by Equipment Type
Hemarina SA Pipeline Products by Development Stage

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report